OpenAI teamed up with biotech firm Ligo to launch BioBasicsBench, evaluating how AI agents interpret raw data across 100 routine wet-lab tasks. Running at maximum reasoning effort, GPT-6 Astra scored 66.7%, comfortably beating GPT-5.6 Sol's 43.8%. Still, the models struggle with control checks and colony counting, showing AI lab assistants aren't ready to fly solo just yet.
Anthropic's biology lab just mapped the first 3D structure of a vault particle from prokaryotic cells, using Claude at every step of the research. Claude helped search protein databases, design DNA constructs, and process cryo-EM data—shrinking a weeks-long modeling process down to 34 hours. Why it matters: Vaults have baffled biologists since 1986, and this shows AI can meaningfully speed up real-world wet-lab discovery.
Neuralink just upgraded its brain implant to hook directly into xAI’s Grok. An ALS patient can now mentally trigger an AI agent to take over the screen, type in iOS apps, and even place phone calls hands-free. Why it matters: Instead of painstakingly clicking cursors pixel by pixel, brains can now issue high-level intent directly to AI agents.
Anthropic just revealed it is running internal drug discovery programs after acquiring Mithril Medicine, a solo-founder biotech that used Claude to advance a muscular dystrophy candidate to mouse tests in 18 months. Claude also designed 35,000 antibodies in a month and cut key regulatory drafting from three months to four hours. While Anthropic warns its drug bets may never yield revenue, its wet-lab push signals a aggressive move into physical science.
Microsoft just unveiled MAI-DxO in Science, an AI diagnostic system that acts like a panel of virtual physicians debating complex cases across rounds. On tough New England Journal of Medicine cases, it hit 83% diagnostic accuracy compared to 36% for doctors using reference materials—all while cutting estimated test costs by more than half. Why it matters: instead of answering one-off multiple-choice questions, the AI learns to order the right sequential tests, moving clinical superintelligence closer to real-world hospital workflows.
Alpha Innovator just open-sourced Sage A1.5, a 35B MoE agentic model built for complex scientific workflows like molecular design and data analysis. It orchestrates parallel subagents, outputs cited reports with figures, and catches its own errors mid-run without external critics. The full release is 72GB, alongside a 22GB Q4 GGUF variant on Hugging Face.
OpenAI, PerturbAI, and Scripps Research just showed off a distributed swarm of thousands of GPT-Rosalind agents analyzing CRISPR data from millions of mouse brain cells in 32 minutes—a task that typically takes humans months to a year. The agents combed literature to surface fresh leads for neurodegenerative diseases like Parkinson's, showing how parallel AI can turn massive biological datasets into testable lab hypotheses.
OpenAI just acquired Orchestra Bio to combine agentic workflows with its Rosalind life sciences suite. The integration is designed to let AI handle coordination hiccups across complex trials and compress the grueling 10-to-15-year drug development cycle for partners like Novo Nordisk and Moderna.
Anthropic's internal Claude model just autonomously engineered protein minibinders against lethal scorpion neurotoxins in a 64-hour campaign. Generating 318,484 candidates using 12 tools, wet-lab testing confirmed 17 of the 211 evaluated designs hit binding targets. Why it matters: It shows AI agents can independently tackle neglected diseases that pharmaceutical companies routinely ignore.
OpenAI just launched the Rosalind Academic Plan, offering eligible U.S. university labs up to 30 free seats for 12 months to access GPT-Rosalind and its life-sciences workbench. Labs get specialized reasoning tools for drug discovery and genomics without their data being used for training. Why it matters: Frontier bio-AI brings huge potential alongside real biosafety concerns, so OpenAI is lowering the cost barrier for vetted academic researchers first, though API access remains excluded.
Google just partnered with the WHO to deploy Earth AI tools that spot disease outbreaks early. Testing during the DRC Ebola outbreak, its Geospatial Reasoning agent identified 48 exposed settlements and over 45,500 at-risk people in minutes rather than weeks. Why it matters: Pairing planetary models with mobility data flips public health from scrambling after viruses to cutting them off weeks ahead.
Google DeepMind just unveiled AlphaProtein Novo, an AI pipeline that builds functional enzymes from scratch without relying on natural templates. The system designs both 3D structures and amino acid sequences, proving itself in wet labs by synthesizing drug compounds and breaking down toxic plastics. The code is now open on GitHub.
Google DeepMind just revealed BOTANIC-1, a plant genome AI paired with Gemma 4 to pinpoint crop-changing mutations. Pretrained on 320 plant species, the pipeline successfully ranked the causal mutation first out of nearly 2,500 candidates 90% of the time, potentially turning years of field trials into hours of compute.
OpenAI just open-sourced MentalHealthBench, a clinical evaluation benchmark built with over 80 licensed psychologists and psychiatrists from 22 countries. It assesses how frontier models handle emotional support across non-acute chat, serious distress, and crisis emergencies. Why it matters: millions already confide in ChatGPT for advice, and this dataset sets clear professional guardrails to keep AI empathetic without crossing dangerous clinical lines.
Anthropic's new life sciences lab deployed roughly 950 parallel Claude agents that combed massive DNA databases over 21 hours, autonomously discovering a novel enzyme system dubbed ART. CRISPR pioneer Feng Zhang called the finding genuinely intriguing, marking a major milestone for autonomous scientific research.
Anthropic just launched the Life Sciences Verification Program (LSVP), giving vetted research teams relaxed biology safeguards across Mythos, Opus, and Sonnet models. Applicants can secure standard or high-risk grants, while enforcement shifts from real-time blocking to offline behavioral monitoring with 30-day retention. Why it matters: Legitimate drug discovery and clinical workflows will finally stop getting tripped up by broad biosecurity filters.
UCSF researchers have demonstrated that a single high-density brain implant can decode speech and physical gestures simultaneously in paralyzed individuals. By running parallel decoders trained on both isolated and concurrent movements, the system controls a personalized virtual avatar in real time, moving brain-computer interfaces closer to natural multimodal communication.
Apple just unveiled the Apple Watch Series 12 and a redesigned Health app powered by Apple Intelligence. The update introduces high-frequency heart tracking, a 0–10 daily readiness score, and camera-based home movement evaluations. Why it matters: Wearables are shifting from passive tracking to proactive AI coaching that turns raw metrics into daily actions.
Google DeepMind just launched AlphaGenome Atlas, a massive database predicting the regulatory impact of all 9 billion single-letter genetic changes in the human genome. It unifies coding and non-coding predictions into a single AVI score, allowing researchers to explore genomic variations through a no-code portal.
Researchers just showed that rentosertib, an AI-designed drug candidate, significantly rolled back patients' biological age during a phase 2a clinical trial. By testing six proteomic aging clocks against serum samples, the team found treated patients shed an average of 2 to 3 years in biological age by week 4. The study proves standard disease trials can successfully double as anti-aging readouts.
